Jennifer Rebecca Snaith

Dr Jennifer Rebecca Snaith is a Research Fellow and Endocrinologist based at the Garvan Institute of Medical Research and St Vincent's Hospital in Sydney, Australia. She holds a PhD from the University of New South Wales and specializes in clinical research related to type 1 diabetes, with a career mission focused on improving the lives of people living with this condition through clinical service, advocacy, and innovative research.

Her educational background includes:

• FRACP (Fellow of the Royal Australasian College of Physicians)
• MBBS (Hons) (Bachelor of Medicine, Bachelor of Surgery with Honors)
• BMedSci (Bachelor of Medical Science)
• PhD from University of New South Wales

Dr Snaith's research focuses on diabetes, endocrinology, metabolism, insulin resistance, and cardiometabolic risk in type 1 diabetes patients. She established the Diabetes in Youth (DIY) service in 2021 with her team (Marhava/Lum/Higgins) at St Vincent's Hospital and conducts clinical trials as part of the Australian Type 1 Diabetes Mellitus Adjuncts Group (AUSTAG), which she co-founded with Prof Jerry Greenfield.

Her work encompasses several significant clinical trials including the INTIMET study examining insulin resistance in type 1 diabetes managed with metformin, the RESET1 study investigating semaglutide's impact on cardiovascular risk, and the TIRTLE study evaluating tirzepatide's effects in type 1 diabetes (due for completion December 2024).

Dr Snaith has received numerous scientific awards and recognitions:

• 2024 - UNSW Dean's Award for Outstanding Thesis
• 2024 - Australian Diabetes Society Lindsey Baudinet Rising Star Award
• 2023 - Diabetes Australia Coghlan Award
• 2022 - JDRF Rebecca Davies Fellowship
• 2022 - Australian Diabetes Society Clinical Young Investigator's Award
• 2020 - NHMRC Post Graduate Scholarship

She has secured significant research funding including the MRFF 2023 TTRA grant ($916,315), Diabetes Australia Coghlan Award ($150,000), and JDRF Rebecca Davies Fellowship ($142,500). Her research aims to prevent cardiovascular disease in type 1 diabetes through novel repurposing of cardioprotective medications.